Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men
Abstract Background 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men. Methods We conducted a randomized, double-blind study at...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 105; no. 3; pp. e835 - e847 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
US
Oxford University Press
01.03.2020
Copyright Oxford University Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract
Background
11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men.
Methods
We conducted a randomized, double-blind study at 2 academic medical centers. 42 healthy men (18–50 years) were randomized to receive oral placebo or 11β-MNTDC, 200 or 400 mg daily, for 28 consecutive days. Primary outcome (safety and tolerability) measures were assessed twice per week. Subjects underwent serial blood sampling over 24 hours on days 1 and 28 to assess secondary outcomes: pharmacokinetics (serum drug concentrations); pharmacodynamics of 11β-MNTDC (serum sex steroids and gonadotropins); and mood and sexual function (via validated questionnaires).
Results
There were no serious adverse events. No participants discontinued because of an adverse event or laboratory test abnormality. 11β-MNTDC resulted in a dose-related increase in serum 11β-MNTDC and 11β-MNT concentrations sustained over 24 hours. Administration of 11β-MNTDC resulted in a marked suppression of serum gonadotropins, T, calculated free T, estradiol, and SHBG over the treatment period (P < 0.01). Adverse effects that may be related to 11β-MNTDC included weight gain, acne, headaches, fatigue, and mild mood changes, with 5 men reporting decreased libido and 3 decreased erectile/ejaculatory function. Serum low-density lipoprotein cholesterol, weight (~2 kg), hematocrit, and hemoglobin increased and serum high-density lipoprotein cholesterol decreased in both 11β-MNTDC groups.
Conclusion
Daily oral 11β-MNTDC for 28 days in healthy men markedly suppressed serum gonadotropin and T concentrations without serious adverse effects. These results warrant further evaluation of 11β-MNTDC as a potential male oral contraceptive. |
|---|---|
| AbstractList | Background 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men. Methods We conducted a randomized, double-blind study at 2 academic medical centers. 42 healthy men (18–50 years) were randomized to receive oral placebo or 11β-MNTDC, 200 or 400 mg daily, for 28 consecutive days. Primary outcome (safety and tolerability) measures were assessed twice per week. Subjects underwent serial blood sampling over 24 hours on days 1 and 28 to assess secondary outcomes: pharmacokinetics (serum drug concentrations); pharmacodynamics of 11β-MNTDC (serum sex steroids and gonadotropins); and mood and sexual function (via validated questionnaires). Results There were no serious adverse events. No participants discontinued because of an adverse event or laboratory test abnormality. 11β-MNTDC resulted in a dose-related increase in serum 11β-MNTDC and 11β-MNT concentrations sustained over 24 hours. Administration of 11β-MNTDC resulted in a marked suppression of serum gonadotropins, T, calculated free T, estradiol, and SHBG over the treatment period (P < 0.01). Adverse effects that may be related to 11β-MNTDC included weight gain, acne, headaches, fatigue, and mild mood changes, with 5 men reporting decreased libido and 3 decreased erectile/ejaculatory function. Serum low-density lipoprotein cholesterol, weight (~2 kg), hematocrit, and hemoglobin increased and serum high-density lipoprotein cholesterol decreased in both 11β-MNTDC groups. Conclusion Daily oral 11β-MNTDC for 28 days in healthy men markedly suppressed serum gonadotropin and T concentrations without serious adverse effects. These results warrant further evaluation of 11β-MNTDC as a potential male oral contraceptive. Abstract Background 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men. Methods We conducted a randomized, double-blind study at 2 academic medical centers. 42 healthy men (18–50 years) were randomized to receive oral placebo or 11β-MNTDC, 200 or 400 mg daily, for 28 consecutive days. Primary outcome (safety and tolerability) measures were assessed twice per week. Subjects underwent serial blood sampling over 24 hours on days 1 and 28 to assess secondary outcomes: pharmacokinetics (serum drug concentrations); pharmacodynamics of 11β-MNTDC (serum sex steroids and gonadotropins); and mood and sexual function (via validated questionnaires). Results There were no serious adverse events. No participants discontinued because of an adverse event or laboratory test abnormality. 11β-MNTDC resulted in a dose-related increase in serum 11β-MNTDC and 11β-MNT concentrations sustained over 24 hours. Administration of 11β-MNTDC resulted in a marked suppression of serum gonadotropins, T, calculated free T, estradiol, and SHBG over the treatment period (P < 0.01). Adverse effects that may be related to 11β-MNTDC included weight gain, acne, headaches, fatigue, and mild mood changes, with 5 men reporting decreased libido and 3 decreased erectile/ejaculatory function. Serum low-density lipoprotein cholesterol, weight (~2 kg), hematocrit, and hemoglobin increased and serum high-density lipoprotein cholesterol decreased in both 11β-MNTDC groups. Conclusion Daily oral 11β-MNTDC for 28 days in healthy men markedly suppressed serum gonadotropin and T concentrations without serious adverse effects. These results warrant further evaluation of 11β-MNTDC as a potential male oral contraceptive. 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men. We conducted a randomized, double-blind study at 2 academic medical centers. 42 healthy men (18-50 years) were randomized to receive oral placebo or 11β-MNTDC, 200 or 400 mg daily, for 28 consecutive days. Primary outcome (safety and tolerability) measures were assessed twice per week. Subjects underwent serial blood sampling over 24 hours on days 1 and 28 to assess secondary outcomes: pharmacokinetics (serum drug concentrations); pharmacodynamics of 11β-MNTDC (serum sex steroids and gonadotropins); and mood and sexual function (via validated questionnaires). There were no serious adverse events. No participants discontinued because of an adverse event or laboratory test abnormality. 11β-MNTDC resulted in a dose-related increase in serum 11β-MNTDC and 11β-MNT concentrations sustained over 24 hours. Administration of 11β-MNTDC resulted in a marked suppression of serum gonadotropins, T, calculated free T, estradiol, and SHBG over the treatment period (P < 0.01). Adverse effects that may be related to 11β-MNTDC included weight gain, acne, headaches, fatigue, and mild mood changes, with 5 men reporting decreased libido and 3 decreased erectile/ejaculatory function. Serum low-density lipoprotein cholesterol, weight (~2 kg), hematocrit, and hemoglobin increased and serum high-density lipoprotein cholesterol decreased in both 11β-MNTDC groups. Daily oral 11β-MNTDC for 28 days in healthy men markedly suppressed serum gonadotropin and T concentrations without serious adverse effects. These results warrant further evaluation of 11β-MNTDC as a potential male oral contraceptive. 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men.BACKGROUND11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men.We conducted a randomized, double-blind study at 2 academic medical centers. 42 healthy men (18-50 years) were randomized to receive oral placebo or 11β-MNTDC, 200 or 400 mg daily, for 28 consecutive days. Primary outcome (safety and tolerability) measures were assessed twice per week. Subjects underwent serial blood sampling over 24 hours on days 1 and 28 to assess secondary outcomes: pharmacokinetics (serum drug concentrations); pharmacodynamics of 11β-MNTDC (serum sex steroids and gonadotropins); and mood and sexual function (via validated questionnaires).METHODSWe conducted a randomized, double-blind study at 2 academic medical centers. 42 healthy men (18-50 years) were randomized to receive oral placebo or 11β-MNTDC, 200 or 400 mg daily, for 28 consecutive days. Primary outcome (safety and tolerability) measures were assessed twice per week. Subjects underwent serial blood sampling over 24 hours on days 1 and 28 to assess secondary outcomes: pharmacokinetics (serum drug concentrations); pharmacodynamics of 11β-MNTDC (serum sex steroids and gonadotropins); and mood and sexual function (via validated questionnaires).There were no serious adverse events. No participants discontinued because of an adverse event or laboratory test abnormality. 11β-MNTDC resulted in a dose-related increase in serum 11β-MNTDC and 11β-MNT concentrations sustained over 24 hours. Administration of 11β-MNTDC resulted in a marked suppression of serum gonadotropins, T, calculated free T, estradiol, and SHBG over the treatment period (P < 0.01). Adverse effects that may be related to 11β-MNTDC included weight gain, acne, headaches, fatigue, and mild mood changes, with 5 men reporting decreased libido and 3 decreased erectile/ejaculatory function. Serum low-density lipoprotein cholesterol, weight (~2 kg), hematocrit, and hemoglobin increased and serum high-density lipoprotein cholesterol decreased in both 11β-MNTDC groups.RESULTSThere were no serious adverse events. No participants discontinued because of an adverse event or laboratory test abnormality. 11β-MNTDC resulted in a dose-related increase in serum 11β-MNTDC and 11β-MNT concentrations sustained over 24 hours. Administration of 11β-MNTDC resulted in a marked suppression of serum gonadotropins, T, calculated free T, estradiol, and SHBG over the treatment period (P < 0.01). Adverse effects that may be related to 11β-MNTDC included weight gain, acne, headaches, fatigue, and mild mood changes, with 5 men reporting decreased libido and 3 decreased erectile/ejaculatory function. Serum low-density lipoprotein cholesterol, weight (~2 kg), hematocrit, and hemoglobin increased and serum high-density lipoprotein cholesterol decreased in both 11β-MNTDC groups.Daily oral 11β-MNTDC for 28 days in healthy men markedly suppressed serum gonadotropin and T concentrations without serious adverse effects. These results warrant further evaluation of 11β-MNTDC as a potential male oral contraceptive.CONCLUSIONDaily oral 11β-MNTDC for 28 days in healthy men markedly suppressed serum gonadotropin and T concentrations without serious adverse effects. These results warrant further evaluation of 11β-MNTDC as a potential male oral contraceptive. |
| Author | Swerdloff, Ronald S Thirumalai, Arthi Hull, Laura Yuen, Fiona Page, Stephanie T Pham, Cindy Anawalt, Bradley D Dart, Clint Long, Jill Wang, Christina Amory, John K Bremner, William J Liu, Peter Y Wu, Hongsheng Blithe, Diana L |
| AuthorAffiliation | Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California Department of Medicine, University of Washington, Seattle, Washington Health Decisions, Durham, North Carolina Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland |
| AuthorAffiliation_xml | – name: Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California Department of Medicine, University of Washington, Seattle, Washington Health Decisions, Durham, North Carolina Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland – name: 1 Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center , Torrance, California – name: 2 Department of Medicine, University of Washington , Seattle, Washington – name: 3 Health Decisions , Durham, North Carolina – name: 4 Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, Maryland |
| Author_xml | – sequence: 1 givenname: Fiona orcidid: 0000-0002-8200-2311 surname: Yuen fullname: Yuen, Fiona organization: Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California – sequence: 2 givenname: Arthi surname: Thirumalai fullname: Thirumalai, Arthi organization: Department of Medicine, University of Washington, Seattle, Washington – sequence: 3 givenname: Cindy surname: Pham fullname: Pham, Cindy organization: Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California – sequence: 4 givenname: Ronald S surname: Swerdloff fullname: Swerdloff, Ronald S organization: Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California – sequence: 5 givenname: Bradley D surname: Anawalt fullname: Anawalt, Bradley D organization: Department of Medicine, University of Washington, Seattle, Washington – sequence: 6 givenname: Peter Y surname: Liu fullname: Liu, Peter Y organization: Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California – sequence: 7 givenname: John K surname: Amory fullname: Amory, John K organization: Department of Medicine, University of Washington, Seattle, Washington – sequence: 8 givenname: William J surname: Bremner fullname: Bremner, William J organization: Department of Medicine, University of Washington, Seattle, Washington – sequence: 9 givenname: Clint surname: Dart fullname: Dart, Clint organization: Health Decisions, Durham, North Carolina – sequence: 10 givenname: Hongsheng surname: Wu fullname: Wu, Hongsheng organization: Health Decisions, Durham, North Carolina – sequence: 11 givenname: Laura surname: Hull fullname: Hull, Laura organization: Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California – sequence: 12 givenname: Diana L surname: Blithe fullname: Blithe, Diana L organization: Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland – sequence: 13 givenname: Jill surname: Long fullname: Long, Jill organization: Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland – sequence: 14 givenname: Christina surname: Wang fullname: Wang, Christina email: wang@lundquist.org organization: Department of Medicine, Division of Endocrinology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California – sequence: 15 givenname: Stephanie T surname: Page fullname: Page, Stephanie T organization: Department of Medicine, University of Washington, Seattle, Washington |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31976519$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc9O3DAYxKOKqiy01x4rS720h4D_JcaXSmgpUImFA1TqzfI6X3YNjh3sBLSv1QfhmeqyS9UioZ58mPmNv9HsFFs-eCiK9wTvEUrwvnHWQ7ffLLTGjL4qJkTyqhREiq1igjElpRT0x3axk9I1xoTzir0ptlnW64rISXF7pK1boYuoHTpsOuttGqIebPAotGhYAjoPd5A138SwAI8IefhZzs6vjqZopuMNNJm-HPs-QkqQ0CXEsUMnwesmDDH01idkPToF7YblCs3Avy1et9oleLd5d4vvx1-vpqfl2cXJt-nhWWl4VdFSmBZjWVMDFSaVEAcgCWtEW8s5zKuGCsYbQyjkqqYlpK4rCZhVLXDD5oJptlt8Wef247yDxoDPxZzqo-10XKmgrfpX8XapFuFOCcwlrUkO-LQJiOF2hDSoziYDzmkPYUyKMs6pIAc1y9aPz6zXYYw-11OUM4KprInMrg9_X_TnlKc1soGvDSaGlCK0ytjhcYx8oHWKYPV7dLUeXW1Gz9jeM-wp-UWAroH74AaI6caN9xDV8nGkl6HPayiM_f8--AV4zNJY |
| CitedBy_id | crossref_primary_10_1080_19419899_2023_2191606 crossref_primary_10_1016_j_ando_2023_03_025 crossref_primary_10_1177_1557988320922443 crossref_primary_10_3390_ijms25115805 crossref_primary_10_1016_j_bmcl_2021_128005 crossref_primary_10_1111_andr_13525 crossref_primary_10_1016_j_fertnstert_2021_03_047 crossref_primary_10_1210_clinem_dgab034 crossref_primary_10_1016_j_ecl_2021_11_005 crossref_primary_10_3389_fendo_2022_891589 crossref_primary_10_3390_jcm14072188 crossref_primary_10_1111_andr_13025 crossref_primary_10_1186_s12610_023_00204_z crossref_primary_10_3390_pharmaceutics16081032 crossref_primary_10_1002_mrd_70000 crossref_primary_10_1016_j_contraception_2021_06_009 crossref_primary_10_1016_j_contraception_2024_110782 crossref_primary_10_1016_j_beem_2022_101627 crossref_primary_10_1097_MED_0000000000000880 crossref_primary_10_1016_j_bpobgyn_2024_102559 crossref_primary_10_1016_j_purol_2023_09_004 crossref_primary_10_1016_j_contraception_2022_04_014 crossref_primary_10_1016_j_ucl_2022_07_008 crossref_primary_10_1111_andr_13699 crossref_primary_10_1124_pharmrev_122_000787 crossref_primary_10_1093_biolre_ioab172 crossref_primary_10_1093_biolre_ioad111 |
| Cites_doi | 10.1210/jc.2017-00196 10.1152/jappl.1989.66.1.498 10.1210/jc.2012-1384 10.1111/j.2047-2927.2014.00216.x 10.1210/jc.2003-031307 10.1056/NEJM199607043350101 10.1016/j.ajog.2004.01.057 10.1016/j.genm.2008.03.011 10.1016/j.bpobgyn.2014.05.008 10.1210/jc.2016-3837 10.1002/j.1939-4640.2003.tb02728.x 10.1363/4309411 10.1172/JCI84137 10.1210/jc.2005-0553 10.1210/jcem-57-3-645 10.1017/S0021932016000560 10.1373/clinchem.2008.103846 10.1093/humrep/15.3.637 10.1016/S2214-109X(18)30029-9 10.2164/jandrol.110.011817 10.1056/NEJMoa0804381 10.1210/jc.2016-2141 10.2337/dc06-1979 10.1111/andr.12303 10.1210/jc.2007-2768 10.1210/en.2005-1524 10.1210/jc.2003-030107 10.1016/j.jsxm.2018.05.008 10.1016/S0015-0282(16)58166-7 10.1111/j.2047-2927.2013.00135.x 10.2164/jandrol.109.009365 10.1093/humrep/deh574 10.1016/j.jsbmb.2010.06.009 10.1210/jc.2018-01528 10.2164/jandrol.110.010371 10.1152/physrev.1972.52.1.198 10.1210/jc.2004-1184 10.1249/01.MSS.0000117157.06455.B0 10.1007/s13669-016-0140-8 10.1016/0010-7824(78)90045-8 10.1177/2042018819834846 10.1093/gerona/glq002 10.1002/j.1939-4640.2004.tb03164.x 10.1046/j.1525-1497.2001.016009606.x 10.1016/j.jsxm.2019.04.003 10.1007/s00392-017-1106-1 10.1055/s-0029-1232561 10.1111/j.1365-2044.2005.04218.x 10.1210/jc.2018-02027 10.1002/j.1939-4640.2003.tb02695.x 10.2164/jandrol.111.013169 10.1210/jcem-33-5-759 10.1111/j.1365-2605.2011.01163.x 10.2337/diacare.28.7.1636 10.1056/NEJMoa1206168 10.1002/j.1939-4640.1994.tb00433.x |
| ContentType | Journal Article |
| Copyright | Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020 Copyright © Oxford University Press 2015 Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020 – notice: Copyright © Oxford University Press 2015 – notice: Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TM 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1210/clinem/dgaa032 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | e847 |
| ExternalDocumentID | PMC7049261 31976519 10_1210_clinem_dgaa032 10.1210/clinem/dgaa032 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: T32 DK007247 – fundername: NHLBI NIH HHS grantid: K24 HL138632 – fundername: NICHD NIH HHS grantid: HHSN275200800044U – fundername: NCATS NIH HHS grantid: UL1 TR001881 – fundername: NICHD NIH HHS grantid: F32 HD097932 – fundername: NCATS NIH HHS grantid: UL1 TR000124 – fundername: NCATS NIH HHS grantid: UL1 TR000423 – fundername: ; ; grantid: HHSN27520130024I – fundername: ; ; grantid: HHSN275201300025I – fundername: ; ; grantid: HHSN2752012002 – fundername: ; ; grantid: K24HL138632 – fundername: ; ; |
| GroupedDBID | --- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 3O- 4.4 48X 53G 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABZA AACZT AAIMJ AAJQQ AAKAS AAPGJ AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYJJ ABBLC ABDFA ABDPE ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABUWG ABVGC ABWST ABXVV ABXZS ACFRR ACGFO ACGFS ACPRK ACUTJ ACVCV ACYHN ACZBC ADBBV ADGKP ADGZP ADHKW ADMTO ADNBA ADQBN ADRTK ADVEK ADZCM AELWJ AEMDU AEMQT AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFQV AFFZL AFGWE AFKRA AFOFC AFRAH AFXAL AFYAG AGINJ AGKRT AGMDO AGQXC AGUTN AHMBA AHMMS AI. AJDVS AJEEA ALMA_UNASSIGNED_HOLDINGS ALXQX APIBT APJGH AQDSO AQKUS ARIXL ASPBG ATGXG AVNTJ AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CCPQU CDBKE CS3 D-I DAKXR DIK E3Z EBS EIHJH EJD EMOBN ENERS F5P FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC GX1 H13 HMCUK HVGLF HZ~ H~9 IAO IHR INH ITC J5H KBUDW KOP KSI KSN L7B M1P M5~ MBLQV MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBFPC OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PHGZT PQQKQ PROAC PSQYO REU ROX ROZ TEORI TJX TLC TMA TR2 TWZ UKHRP VH1 VVN W8F WHG WOQ X52 X7M YBU YFH YHG YOC YSK ZGI ZXP ZY1 ~02 ~H1 AEOTA AGORE AJBYB NU- PHGZM AAYXX AHGBF CITATION CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7QP 7T5 7TM 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c4552-7cf00962ce5015778e913d7f69beb5d2734dc12e719cf116659e035fe4c3b73a3 |
| IEDL.DBID | 7X7 |
| ISSN | 0021-972X 1945-7197 |
| IngestDate | Thu Aug 21 18:21:39 EDT 2025 Fri Jul 11 08:32:45 EDT 2025 Fri Jul 25 22:00:12 EDT 2025 Mon Jul 21 06:05:08 EDT 2025 Tue Jul 01 01:10:55 EDT 2025 Thu Apr 24 22:57:26 EDT 2025 Fri May 16 03:41:27 EDT 2025 Wed Apr 02 07:02:00 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | gonadotropins androgen progestin male hormonal contraception testosterone suppression |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4552-7cf00962ce5015778e913d7f69beb5d2734dc12e719cf116659e035fe4c3b73a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 F.Y., A.T., and C.P. contributed equally as first authors; C.W. and S.T.P. contributed equally as senior authors. |
| ORCID | 0000-0002-8200-2311 |
| PMID | 31976519 |
| PQID | 2431029619 |
| PQPubID | 2046206 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7049261 proquest_miscellaneous_2344271863 proquest_journals_2431029619 pubmed_primary_31976519 crossref_citationtrail_10_1210_clinem_dgaa032 crossref_primary_10_1210_clinem_dgaa032 wolterskluwer_health_10_1210_clinem_dgaa032 oup_primary_10_1210_clinem_dgaa032 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-03-01 |
| PublicationDateYYYYMMDD | 2020-03-01 |
| PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2020 |
| Publisher | Oxford University Press Copyright Oxford University Press |
| Publisher_xml | – name: Oxford University Press – name: Copyright Oxford University Press |
| References | Westaby (2021122102412745400_CIT0021) 1977; 2 Sathyanarayana (2021122102412745400_CIT0030) 2017; 102 Büchter (2021122102412745400_CIT0060) 1999; 107 Yuen (2021122102412745400_CIT0024) 2019 Attardi (2021122102412745400_CIT0016) 2010; 122 Bhasin (2021122102412745400_CIT0051) 2005; 90 Behre (2021122102412745400_CIT0039) 2016; 101 van Marken Lichtenbelt (2021122102412745400_CIT0052) 2004; 36 Martin (2021122102412745400_CIT0013) 2000; 15 Ayoub (2021122102412745400_CIT0022) 2017; 5 Meriggiola (2021122102412745400_CIT0008) 2003; 24 Stephens-Shields (2021122102412745400_CIT0032) 2019; 16 Liu (2021122102412745400_CIT0007) 2008; 93 Shiraishi (2021122102412745400_CIT0029) 2008; 54 Turner (2021122102412745400_CIT0040) 2003; 88 Vermeulen (2021122102412745400_CIT0025) 1971; 33 Kam (2021122102412745400_CIT0055) 2005; 60 Ding (2021122102412745400_CIT0044) 2009; 361 Gooren (2021122102412745400_CIT0012) 1994; 15 Heinemann (2021122102412745400_CIT0014) 2005; 20 Finkelstein (2021122102412745400_CIT0049) 2016; 126 Ross (2021122102412745400_CIT0003) 2017; 49 Attardi (2021122102412745400_CIT0019) 2011; 32 Lee (2021122102412745400_CIT0027) 2003; 24 World Health Organization. (2021122102412745400_CIT0031) 2010 Ilani (2021122102412745400_CIT0042) 2012; 97 Finkelstein (2021122102412745400_CIT0048) 2013; 369 Chao (2021122102412745400_CIT0005) 2014; 28 Yin (2021122102412745400_CIT0011) 2012; 33 Bagatell (2021122102412745400_CIT0059) 1994; 79 Sonfield (2021122102412745400_CIT0002) 2011; 43 Wu (2021122102412745400_CIT0037) 1996; 65 Wang (2021122102412745400_CIT0028) 2018; 15 Griggs (2021122102412745400_CIT0036) 1989; 66 Lakshman (2021122102412745400_CIT0045) 2010; 65 Gagliano-Jucá (2021122102412745400_CIT0034) 2017; 102 Wu (2021122102412745400_CIT0018) 2019; 104 Schwartz (2021122102412745400_CIT0035) 2011; 34 Wang (2021122102412745400_CIT0009) 2004; 190 März (2021122102412745400_CIT0057) 2017; 106 Clermont (2021122102412745400_CIT0038) 1972; 52 Plymate (2021122102412745400_CIT0043) 1983; 57 Rajala (2021122102412745400_CIT0047) 2007; 30 Attardi (2021122102412745400_CIT0015) 2006; 147 Attardi (2021122102412745400_CIT0017) 2011; 32 Roth (2021122102412745400_CIT0033) 2013; 1 Johannsson (2021122102412745400_CIT0053) 2005; 90 Bhasin (2021122102412745400_CIT0050) 1996; 335 Pitteloud (2021122102412745400_CIT0046) 2005; 28 Gava (2021122102412745400_CIT0056) 2019; 10 Kroenke (2021122102412745400_CIT0026) 2001; 16 Bearak (2021122102412745400_CIT0001) 2018; 6 Quigley (2021122102412745400_CIT0054) 2008; 5 Wang (2021122102412745400_CIT0004) 2016; 5 Hild (2021122102412745400_CIT0020) 2010; 31 Nieschlag (2021122102412745400_CIT0010) 1978; 18 Coviello (2021122102412745400_CIT0006) 2004; 25 Gu (2021122102412745400_CIT0041) 2004; 89 Surampudi (2021122102412745400_CIT0023) 2014; 2 Adorni (2021122102412745400_CIT0058) 2019; 104 |
| References_xml | – volume: 102 start-page: 1478 issue: 5 year: 2017 ident: 2021122102412745400_CIT0034 article-title: Effects of testosterone replacement on electrocardiographic parameters in men: findings from two randomized trials publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2017-00196 – volume: 66 start-page: 498 issue: 1 year: 1989 ident: 2021122102412745400_CIT0036 article-title: Effect of testosterone on muscle mass and muscle protein synthesis publication-title: J Appl Physiol (1985). doi: 10.1152/jappl.1989.66.1.498 – volume: 97 start-page: 3476 issue: 10 year: 2012 ident: 2021122102412745400_CIT0042 article-title: A new combination of testosterone and nestorone transdermal gels for male hormonal contraception publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2012-1384 – volume: 2 start-page: 579 issue: 4 year: 2014 ident: 2021122102412745400_CIT0023 article-title: Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive publication-title: Andrology. doi: 10.1111/j.2047-2927.2014.00216.x – volume: 89 start-page: 2254 issue: 5 year: 2004 ident: 2021122102412745400_CIT0041 article-title: Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2003-031307 – volume: 335 start-page: 1 issue: 1 year: 1996 ident: 2021122102412745400_CIT0050 article-title: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men publication-title: N Engl J Med. doi: 10.1056/NEJM199607043350101 – volume: 190 start-page: S60 issue: 4 Suppl year: 2004 ident: 2021122102412745400_CIT0009 article-title: Male hormonal contraception publication-title: Am J Obstet Gynecol. doi: 10.1016/j.ajog.2004.01.057 – volume: 5 start-page: S114 year: 2008 ident: 2021122102412745400_CIT0054 article-title: Androgens stimulate proximal tubule transport publication-title: Gend Med. doi: 10.1016/j.genm.2008.03.011 – volume: 28 start-page: 845 issue: 6 year: 2014 ident: 2021122102412745400_CIT0005 article-title: Male contraception publication-title: Best Pract Res Clin Obstet Gynaecol. doi: 10.1016/j.bpobgyn.2014.05.008 – volume: 102 start-page: 1870 issue: 6 year: 2017 ident: 2021122102412745400_CIT0030 article-title: Early prenatal phthalate exposure, sex steroid hormones, and birth outcomes publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2016-3837 – volume: 24 start-page: 688 issue: 5 year: 2003 ident: 2021122102412745400_CIT0027 article-title: A simple self-report diary for assessing psychosexual function in hypogonadal men publication-title: J Androl. doi: 10.1002/j.1939-4640.2003.tb02728.x – volume: 43 start-page: 94 issue: 2 year: 2011 ident: 2021122102412745400_CIT0002 article-title: The public costs of births resulting from unintended pregnancies: national and state-level estimates publication-title: Perspect Sex Reprod Health. doi: 10.1363/4309411 – volume: 126 start-page: 1114 issue: 3 year: 2016 ident: 2021122102412745400_CIT0049 article-title: Gonadal steroid-dependent effects on bone turnover and bone mineral density in men publication-title: J Clin Invest. doi: 10.1172/JCI84137 – volume: 90 start-page: 3989 issue: 7 year: 2005 ident: 2021122102412745400_CIT0053 article-title: Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2005-0553 – volume: 57 start-page: 645 issue: 3 year: 1983 ident: 2021122102412745400_CIT0043 article-title: Sex hormone-binding globulin changes with androgen replacement publication-title: J Clin Endocrinol Metab. doi: 10.1210/jcem-57-3-645 – volume: 49 start-page: 648 issue: 5 year: 2017 ident: 2021122102412745400_CIT0003 article-title: Use of male methods of contraception worldwide publication-title: J Biosoc Sci. doi: 10.1017/S0021932016000560 – volume: 54 start-page: 1855 issue: 11 year: 2008 ident: 2021122102412745400_CIT0029 article-title: Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry publication-title: Clin Chem. doi: 10.1373/clinchem.2008.103846 – volume: 15 start-page: 637 issue: 3 year: 2000 ident: 2021122102412745400_CIT0013 article-title: Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations publication-title: Hum Reprod. doi: 10.1093/humrep/15.3.637 – volume: 6 start-page: e380 issue: 4 year: 2018 ident: 2021122102412745400_CIT0001 article-title: Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model publication-title: Lancet Glob Health. doi: 10.1016/S2214-109X(18)30029-9 – volume: 32 start-page: 530 issue: 5 year: 2011 ident: 2021122102412745400_CIT0017 article-title: Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits publication-title: J Androl. doi: 10.2164/jandrol.110.011817 – volume: 361 start-page: 1152 issue: 12 year: 2009 ident: 2021122102412745400_CIT0044 article-title: Sex hormone-binding globulin and risk of type 2 diabetes in women and men publication-title: N Engl J Med. doi: 10.1056/NEJMoa0804381 – volume: 101 start-page: 4779 issue: 12 year: 2016 ident: 2021122102412745400_CIT0039 article-title: Efficacy and safety of an injectable combination hormonal contraceptive for men publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2016-2141 – volume: 30 start-page: e13 issue: 4 year: 2007 ident: 2021122102412745400_CIT0047 article-title: Associations of total testosterone and sex hormone-binding globulin levels with insulin sensitivity in middle-aged Finnish men publication-title: Diabetes Care. doi: 10.2337/dc06-1979 – volume: 5 start-page: 278 issue: 2 year: 2017 ident: 2021122102412745400_CIT0022 article-title: Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive publication-title: Andrology. doi: 10.1111/andr.12303 – volume: 93 start-page: 1774 issue: 5 year: 2008 ident: 2021122102412745400_CIT0007 article-title: Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2007-2768 – volume: 147 start-page: 3016 issue: 6 year: 2006 ident: 2021122102412745400_CIT0015 article-title: Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity publication-title: Endocrinology. doi: 10.1210/en.2005-1524 – volume: 88 start-page: 4659 issue: 10 year: 2003 ident: 2021122102412745400_CIT0040 article-title: Contraceptive efficacy of a depot progestin and androgen combination in men publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2003-030107 – volume: 15 start-page: 997 issue: 7 year: 2018 ident: 2021122102412745400_CIT0028 article-title: Validity and clinically meaningful changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: results from the Testosterone Trials publication-title: J Sex Med. doi: 10.1016/j.jsxm.2018.05.008 – volume: 65 start-page: 626 issue: 3 year: 1996 ident: 2021122102412745400_CIT0037 article-title: Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization task force on methods for the regulation of male fertility publication-title: Fertil Steril. doi: 10.1016/S0015-0282(16)58166-7 – volume: 1 start-page: 899 issue: 6 year: 2013 ident: 2021122102412745400_CIT0033 article-title: Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels publication-title: Andrology. doi: 10.1111/j.2047-2927.2013.00135.x – volume: 31 start-page: 472 issue: 5 year: 2010 ident: 2021122102412745400_CIT0020 article-title: Effects of synthetic androgens on liver function using the rabbit as a model publication-title: J Androl. doi: 10.2164/jandrol.109.009365 – volume: 20 start-page: 549 issue: 2 year: 2005 ident: 2021122102412745400_CIT0014 article-title: Attitudes toward male fertility control: results of a multinational survey on four continents publication-title: Hum Reprod. doi: 10.1093/humrep/deh574 – volume: 122 start-page: 212 issue: 4 year: 2010 ident: 2021122102412745400_CIT0016 article-title: The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects publication-title: J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2010.06.009 – volume: 104 start-page: 629 issue: 3 year: 2019 ident: 2021122102412745400_CIT0018 article-title: Safety and pharmacokinetics of single-dose novel oral androgen 11β-methyl-19-nortestosterone-17β-dodecylcarbonate in men publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2018-01528 – volume-title: World Health Organization Laboratory Manual for the Examination and Processing of Human Semen year: 2010 ident: 2021122102412745400_CIT0031 – volume: 2 start-page: 262 issue: 8032 year: 1977 ident: 2021122102412745400_CIT0021 article-title: Liver damage from long-term methyltestosterone publication-title: Lancet. – volume: 32 start-page: 183 issue: 2 year: 2011 ident: 2021122102412745400_CIT0019 article-title: Long-term effects of dimethandrolone 17β-undecanoate and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats publication-title: J Androl. doi: 10.2164/jandrol.110.010371 – year: 2019 ident: 2021122102412745400_CIT0024 – volume: 79 start-page: 561 issue: 2 year: 1994 ident: 2021122102412745400_CIT0059 article-title: Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men publication-title: J Clin Endocrinol Metab. – volume: 52 start-page: 198 issue: 1 year: 1972 ident: 2021122102412745400_CIT0038 article-title: Kinetics of spermatogenesis in mammals: seminiferous epithelium cycle and spermatogonial renewal publication-title: Physiol Rev. doi: 10.1152/physrev.1972.52.1.198 – volume: 90 start-page: 678 issue: 2 year: 2005 ident: 2021122102412745400_CIT0051 article-title: Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2004-1184 – volume: 36 start-page: 484 issue: 3 year: 2004 ident: 2021122102412745400_CIT0052 article-title: Bodybuilders’ body composition: effect of nandrolone decanoate publication-title: Med Sci Sports Exerc. doi: 10.1249/01.MSS.0000117157.06455.B0 – volume: 5 start-page: 38 year: 2016 ident: 2021122102412745400_CIT0004 article-title: Male hormonal contraception: where are we now? publication-title: Curr Obstet Gynecol Rep. doi: 10.1007/s13669-016-0140-8 – volume: 18 start-page: 607 issue: 6 year: 1978 ident: 2021122102412745400_CIT0010 article-title: Clinical trial with testosterone undecanoate for male fertility control publication-title: Contraception. doi: 10.1016/0010-7824(78)90045-8 – volume: 10 start-page: 2042018819834846 year: 2019 ident: 2021122102412745400_CIT0056 article-title: Update on male hormonal contraception publication-title: Ther Adv Endocrinol Metab. doi: 10.1177/2042018819834846 – volume: 65 start-page: 503 issue: 5 year: 2010 ident: 2021122102412745400_CIT0045 article-title: Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men publication-title: J Gerontol A Biol Sci Med Sci. doi: 10.1093/gerona/glq002 – volume: 25 start-page: 931 issue: 6 year: 2004 ident: 2021122102412745400_CIT0006 article-title: Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen publication-title: J Androl. doi: 10.1002/j.1939-4640.2004.tb03164.x – volume: 16 start-page: 606 issue: 9 year: 2001 ident: 2021122102412745400_CIT0026 article-title: The PHQ-9: validity of a brief depression severity measure publication-title: J Gen Intern Med. doi: 10.1046/j.1525-1497.2001.016009606.x – volume: 16 start-page: 951 issue: 7 year: 2019 ident: 2021122102412745400_CIT0032 article-title: Clinically meaningful change in sexual desire in the psychosexual daily questionnaire in older men from the ttrials publication-title: J Sex Med. doi: 10.1016/j.jsxm.2019.04.003 – volume: 106 start-page: 663 issue: 9 year: 2017 ident: 2021122102412745400_CIT0057 article-title: HDL cholesterol: reappraisal of its clinical relevance publication-title: Clin Res Cardiol. doi: 10.1007/s00392-017-1106-1 – volume: 107 start-page: 522 issue: 8 year: 1999 ident: 2021122102412745400_CIT0060 article-title: Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin publication-title: Exp Clin Endocrinol Diabetes. doi: 10.1055/s-0029-1232561 – volume: 60 start-page: 685 issue: 7 year: 2005 ident: 2021122102412745400_CIT0055 article-title: Anabolic steroid abuse: physiological and anaesthetic considerations publication-title: Anaesthesia. doi: 10.1111/j.1365-2044.2005.04218.x – volume: 104 start-page: 3097 issue: 8 year: 2019 ident: 2021122102412745400_CIT0058 article-title: High-density lipoprotein function is reduced in patients affected by genetic or idiopathic hypogonadism publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2018-02027 – volume: 24 start-page: 466 issue: 4 year: 2003 ident: 2021122102412745400_CIT0008 article-title: A review of androgen-progestin regimens for male contraception publication-title: J Androl. doi: 10.1002/j.1939-4640.2003.tb02695.x – volume: 33 start-page: 190 issue: 2 year: 2012 ident: 2021122102412745400_CIT0011 article-title: Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation publication-title: J Androl. doi: 10.2164/jandrol.111.013169 – volume: 33 start-page: 759 issue: 5 year: 1971 ident: 2021122102412745400_CIT0025 article-title: The apparent free testosterone concentration, an index of androgenicity publication-title: J Clin Endocrinol Metab. doi: 10.1210/jcem-33-5-759 – volume: 34 start-page: e415 issue: 5 Pt 2 year: 2011 ident: 2021122102412745400_CIT0035 article-title: Effects of testosterone on the Q-T interval in older men and older women with chronic heart failure publication-title: Int J Androl. doi: 10.1111/j.1365-2605.2011.01163.x – volume: 28 start-page: 1636 issue: 7 year: 2005 ident: 2021122102412745400_CIT0046 article-title: Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men publication-title: Diabetes Care. doi: 10.2337/diacare.28.7.1636 – volume: 369 start-page: 1011 issue: 11 year: 2013 ident: 2021122102412745400_CIT0048 article-title: Gonadal steroids and body composition, strength, and sexual function in men publication-title: N Engl J Med. doi: 10.1056/NEJMoa1206168 – volume: 15 start-page: 212 issue: 3 year: 1994 ident: 2021122102412745400_CIT0012 article-title: A ten-year safety study of the oral androgen testosterone undecanoate publication-title: J Androl. doi: 10.1002/j.1939-4640.1994.tb00433.x |
| SSID | ssj0014453 |
| Score | 2.4834235 |
| Snippet | Abstract
Background
11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of... 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT... Background 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the... |
| SourceID | pubmedcentral proquest pubmed crossref wolterskluwer oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e835 |
| SubjectTerms | 17β-Estradiol Acne Administration, Oral Adolescent Adult Cholesterol Contraception - methods Contraceptive Agents, Male - administration & dosage Contraceptive Agents, Male - adverse effects Contraceptive Agents, Male - pharmacokinetics Double-Blind Method Down-Regulation - drug effects Drug Administration Schedule Estrenes - administration & dosage Estrenes - adverse effects Estrenes - pharmacokinetics Gonadotropins Gonadotropins - blood Headache Healthy Volunteers Hematocrit Hemoglobin Humans Male Middle Aged Mood Online Only Oral administration Pharmacodynamics Pharmacokinetics Pituitary (anterior) Sex hormones Side effects Testosterone Young Adult |
| Title | Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31976519 https://www.proquest.com/docview/2431029619 https://www.proquest.com/docview/2344271863 https://pubmed.ncbi.nlm.nih.gov/PMC7049261 |
| Volume | 105 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3bbtQwELWglSokhArlslAqg5B4QBGJHdvJEyq9UFXaBaFW2rfI8QVWlKTddEH9rX5Iv4mZxBsaodJnTxI5M_acsWfOEPIml0pZAG2RzWQKAYpSkc5MHJWA5sD_eEAoGCiOJ_LgOD2cimk4cGtCWuVyT2w3alsbPCN_z8DTxSwHvP_h9CzCrlF4uxpaaNwlq0hdhildatoHXBArBBZKTENQbBpIG7FqBesOHbz9m9YxZwOnNCh0u4Y3_02bvP-7xivt5keb0X7NL-2vkwcBUNLtzgIekjuuekTWxuHKfIOc7erZyQX9PEehAVMurT0F-Ecn9S8HY8hcANZEk-TqMhpPjnZ3KBbyOAtPY-_PlmW8obC5LH7STwDgIZ6dY7lVQ2cV7cqZLujYVY_J8f7e0c5BFPosRCYVAgC28RjJMOMEgAOlMpcn3Cov89KVwiIBjjUJcyrJjU8SKUXuYi68Sw0vFdf8CVmp6so9IxTEtBeGeVuyNIt1bmPpvbFZqa3wPBmRaPmjCxNIyLEXxkmBwQgopugUUwTFjMjbXv60o9-4UfI16O1Woc2lWouwVpvir2WNyKt-GFYZXp3oytULkOFpysCNSz4iTzsr6D8Fm5iSAp9WA_voBZDBezhSzb63TN4qRr5G-CvvBpZUdDWwN0zi-f8n8YLcY3gm0ObJbZKV8_nCvQTgdF5utatji6x-3Jt8-foHV9EdAA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVIJKCPEmUGBBIA6Vhb1ee-0DQtC0pLQ2CKVSbsbeR4kodhs3VPlTHPgh_CZm_KIWKpx63nGi9czOfuOZ-YaQZ6EvhALQZqnA5xCgCGGlgbStDNAc3D8GEAoGilHsj_f5-6k3XSE_2l4YLKtsfWLlqFUh8Rv5SwY3nc1CwPuvj44tnBqF2dV2hEZtFrt6eQohW_lqZwT6fc7Y9tZkc2w1UwUsyT0P4KQ0iNuZ1B5chUIEOnRcJYwfZjrzFNK9KOkwLZxQGsfxfS_UtusZzaWbCTd14XcvkVXuQigzIKtvt-KPn7q8BecN7yUWPgg2bWgisU8GOx017OcgTW2X9a7BXmvdGYT7d6Hm1dMCk-jl16qG_sxNuH2dXGsgLH1T29wNsqLzm-Ry1CTpb5HjUTo7XNIPcxTqcfPSwlAAnDQuvmtYQ64EsF_qOL9-WlE8GW1SbB3SCp7GaaMVr3lJwZ0tvtF3EDJABD3HBq-SznJaN1AtaaTz22T_QnRwhwzyItf3CAWx1HiSGZUxHthpqGzfGKmCLFWecZ0hsdoXnciG9hynbxwmGP6AYpJaMUmjmCF50ckf1YQf50o-Bb39V2i9VWvSeIcy-WPLQ_KkW4ZzjcmaNNfFAmRczhkAB98dkru1FXR_BW5T-B4-LXr20QkgZ3h_JZ99qbjDhY0MkfBWNnqWlNRdt-ds4v6_N_GYXBlPor1kbyfefUDWGH6RqKr01sngZL7QDwG2nWSPmrNCyeeLPp6_AWqsWEU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Daily+Oral+Administration+of+the+Novel+Androgen+11%CE%B2-MNTDC+Markedly+Suppresses+Serum+Gonadotropins+in+Healthy+Men&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Yuen%2C+Fiona&rft.au=Thirumalai%2C+Arthi&rft.au=Pham%2C+Cindy&rft.au=Swerdloff%2C+Ronald+S&rft.date=2020-03-01&rft.issn=1945-7197&rft.eissn=1945-7197&rft.volume=105&rft.issue=3&rft_id=info:doi/10.1210%2Fclinem%2Fdgaa032&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |